PMID- 28796587
OWN - NLM
STAT- MEDLINE
DCOM- 20171002
LR  - 20190204
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 35
IP  - 27
DP  - 2017 Sep 20
TI  - Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized
      Prostate Cancer.
PG  - 3097-3104
LID - 10.1200/JCO.2017.73.9987 [doi]
AB  - Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate
      cancer decreases the number of deaths from this disease. Surrogates for overall
      survival (OS) could expedite the evaluation of new adjuvant therapies. Methods By
      June 2013, 102 completed or ongoing randomized trials were identified and
      individual patient data were collected from 28 trials with 28,905 patients.
      Disease-free survival (DFS) and metastasis-free survival (MFS) were determined
      for 21,140 patients from 24 trials and 12,712 patients from 19 trials,
      respectively. We evaluated the surrogacy of DFS and MFS for OS by using a
      two-stage meta-analytic validation model by determining the correlation of an
      intermediate clinical end point with OS and the correlation of treatment effects 
      on both the intermediate clinical end point and OS. Results Trials enrolled
      patients from 1987 to 2011. After a median follow-up of 10 years, 45% of 21,140
      men and 45% of 12,712 men experienced a DFS and MFS event, respectively. For DFS 
      and MFS, 61% and 90% of the patients, respectively, were from radiation trials,
      and 63% and 66%, respectively, had high-risk disease. At the patient level,
      Kendall's tau correlation with OS was 0.85 and 0.91 for DFS and MFS,
      respectively. At the trial level, R(2) was 0.86 (95% CI, 0.78 to 0.90) and 0.83
      (95% CI, 0.71 to 0.88) from weighted linear regression of 8-year OS rates versus 
      5-year DFS and MFS rates, respectively. Treatment effects-measured by log hazard 
      ratios-for the surrogates and OS were well correlated ( R(2), 0.73 [95% CI, 0.53 
      to 0.82] for DFS and 0.92 [95% CI, 0.81 to 0.95] for MFS). Conclusion MFS is a
      strong surrogate for OS for localized prostate cancer that is associated with a
      significant risk of death from prostate cancer.
FAU - Xie, Wanling
AU  - Xie W
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Regan, Meredith M
AU  - Regan MM
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Buyse, Marc
AU  - Buyse M
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Halabi, Susan
AU  - Halabi S
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Kantoff, Philip W
AU  - Kantoff PW
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Sartor, Oliver
AU  - Sartor O
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Soule, Howard
AU  - Soule H
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Clarke, Noel W
AU  - Clarke NW
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Collette, Laurence
AU  - Collette L
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Dignam, James J
AU  - Dignam JJ
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Fizazi, Karim
AU  - Fizazi K
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Paruleker, Wendy R
AU  - Paruleker WR
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Sandler, Howard M
AU  - Sandler HM
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Sydes, Matthew R
AU  - Sydes MR
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Tombal, Bertrand
AU  - Tombal B
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Williams, Scott G
AU  - Williams SG
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
FAU - Sweeney, Christopher J
AU  - Sweeney CJ
AD  - Wanling Xie, Meredith M. Regan, and Christopher J. Sweeney, Dana-Farber Cancer
      Institute, Boston, MA; Marc Buyse, International Drug Development Institute;
      Bertrand Tombal, Universite Catholique de Louvain, Louvain-la-Neuve; Laurence
      Collette, European Organisation for Research and Treatment of Cancer, Brussels,
      Belgium; Susan Halabi, Duke University Medical Center, Durham, NC; Philip W.
      Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; Oliver Sartor,
      Tulane Medical School, New Orleans, LA; Howard Soule, Prostate Cancer Foundation,
      Santa Monica; Howard M. Sandler, Cedars-Sinai Medical Center, Los Angeles, CA;
      Noel W. Clarke, The Christie NHS Foundation Trust, Manchester; Matthew R. Sydes, 
      University College London, London, United Kingdom; James J. Dignam, University of
      Chicago, Chicago, IL; Karim Fizazi, Institut Gustave-Roussy, Villejuif, France;
      Wendy R. Paruleker, Canadian Cancer Trials Group, Kingston, Ontario, Canada; and 
      Scott G. Williams, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
CN  - ICECaP Working Group
LA  - eng
GR  - MC_UU_12023/25/Medical Research Council/United Kingdom
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20170810
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of
      Clinical Oncology
JID - 8309333
SB  - IM
CIN - Ann Transl Med. 2017 Dec;5(24):502. PMID: 29299463
CIN - Eur Urol. 2018 Jan;73(1):141-142. PMID: 29033103
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Endpoint Determination
MH  - Humans
MH  - Male
MH  - Neoplasm Metastasis
MH  - Prostatic Neoplasms/*pathology/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - *Survival Analysis
PMC - PMC5652387
IR  - Andren O
FIR - Andren, Ove
IR  - Armstrong J
FIR - Armstrong, John
IR  - Berry D
FIR - Berry, Donald
IR  - Bolla M
FIR - Bolla, Michel
IR  - Buyse M
FIR - Buyse, Marc
IR  - Chin J
FIR - Chin, Joseph
IR  - Chowdhury S
FIR - Chowdhury, Simon
IR  - Clarke N
FIR - Clarke, Noel
IR  - Collette L
FIR - Collette, Laurence
IR  - Cooperberg M
FIR - Cooperberg, Matthew
IR  - Denham J
FIR - Denham, Jim
IR  - Dignam J
FIR - Dignam, James
IR  - Mauro Di Stasi S
FIR - Mauro Di Stasi, Savino
IR  - Eisenberger M
FIR - Eisenberger, Mario
IR  - Fizazi K
FIR - Fizazi, Karim
IR  - Freidlin B
FIR - Freidlin, Boris
IR  - Gillessen S
FIR - Gillessen, Silke
IR  - Gleave M
FIR - Gleave, Martin
IR  - Habibian M
FIR - Habibian, Muriel
IR  - Halabi S
FIR - Halabi, Susan
IR  - James N
FIR - James, Nicholas
IR  - Jarow J
FIR - Jarow, Jonathan
IR  - Kantoff P
FIR - Kantoff, Philip
IR  - Keating N
FIR - Keating, Nancy
IR  - Keloff G
FIR - Keloff, Gary
IR  - Klotz L
FIR - Klotz, Laurence
IR  - Lukka H
FIR - Lukka, Himu
IR  - Mason M
FIR - Mason, Malcolm
IR  - Miyahira A
FIR - Miyahira, Andrea
IR  - Mottet N
FIR - Mottet, Nicolas
IR  - Nakabayashi M
FIR - Nakabayashi, Mari
IR  - Parulekar WR
FIR - Parulekar, Wendy R.
IR  - Regan M
FIR - Regan, Meredith
IR  - Sandler H
FIR - Sandler, Howard
IR  - Sartor O
FIR - Sartor, Oliver
IR  - Scardino P
FIR - Scardino, Peter
IR  - Scher H
FIR - Scher, Howard
IR  - Simon R
FIR - Simon, Richard
IR  - Simons J
FIR - Simons, Jonathan
IR  - Small E
FIR - Small, Eric
IR  - Soule H
FIR - Soule, Howard
IR  - Sweeney CJ
FIR - Sweeney, Christopher J.
IR  - Sydes M
FIR - Sydes, Matthew
IR  - Tangen C
FIR - Tangen, Catherine
IR  - Thompson I
FIR - Thompson, Ian
IR  - Tombal B
FIR - Tombal, Bertrand
IR  - Widmark A
FIR - Widmark, Anders
IR  - Wiegel T
FIR - Wiegel, Thomas
IR  - Wirth M
FIR - Wirth, Manfred
IR  - Williams S
FIR - Williams, Scott
IR  - Xie W
FIR - Xie, Wanling
IR  - Yeoh E
FIR - Yeoh, Eric
IR  - Zapatero A
FIR - Zapatero, Almudena
EDAT- 2017/08/11 06:00
MHDA- 2017/10/03 06:00
CRDT- 2017/08/11 06:00
PHST- 2017/08/11 06:00 [pubmed]
PHST- 2017/10/03 06:00 [medline]
PHST- 2017/08/11 06:00 [entrez]
AID - 10.1200/JCO.2017.73.9987 [doi]
PST - ppublish
SO  - J Clin Oncol. 2017 Sep 20;35(27):3097-3104. doi: 10.1200/JCO.2017.73.9987. Epub
      2017 Aug 10.